Jeremy Davis, MD
Internal Medicine · Little Rock, ARNPI 1770566796
Payments from drug & device makers
Across 1,045 payments — averaging $16.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$6K
- Johnson & Johnson$3K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Pfizer$938
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$812
- Regeneron Healthcare Solutions, Inc.$737
- plus $4K from 27 others
What the payments were for
- Food & beverage$16,55598%
- Education$2802%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 392 | $6,197 |
| Johnson & Johnson | 132 | $2,838 |
| Takeda Pharmaceuticals U.S.A., Inc. | 104 | $1,494 |
| Pfizer | 60 | $938 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 63 | $812 |
| Regeneron Healthcare Solutions, Inc. | 30 | $737 |
| Ferring Pharmaceuticals Inc. | 30 | $453 |
| Merck | 23 | $439 |
| Gilead | 28 | $387 |
| Ironwood Pharmaceuticals, Inc | 33 | $363 |
| Bristol Myers Squibb | 32 | $361 |
| Nestle Healthcare Nutrition Inc. | 27 | $322 |
| Aimmune Therapeutics, Inc. | 10 | $206 |
| Intercept Pharmaceuticals, Inc. | 10 | $173 |
| Braintree Laboratories, Inc. | 17 | $164 |
| Lilly USA, LLC | 8 | $142 |
| Phathom Pharmaceuticals, Inc. | 11 | $125 |
| Boehringer Ingelheim | 1 | $111 |
| Ipsen Biopharmaceuticals, Inc | 4 | $84 |
| Redhill Biopharma Inc. | 5 | $81 |
| Organon | 5 | $77 |
| Madrigal Pharmaceuticals | 2 | $69 |
| QOL Medical, LLC | 3 | $56 |
| Sanofi | 2 | $51 |
| Evoke Pharma, Inc. | 1 | $34 |
| Medtronic | 2 | $31 |
| Mallinckrodt Hospital Products Inc. | 1 | $18 |
| Amgen | 1 | $17 |
| Novo Nordisk | 1 | $16 |
| UCB, Inc. | 1 | $15 |
| Janssen Scientific Affairs, LLC | 1 | $14 |
| Micro-tech Endoscopy USA, Inc. | 1 | $11 |
| Gastrogpo, LLC | 4 | $0 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,835 in reported general payments places this provider in the 95th percentile of 614 internal medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 11 | $317,975 |
| LinzessLinaclotide | 119 | $95,927 |
| CreonLipase/Protease/Amylase | 20 | $45,644 |
| Dexlansoprazole DrDexlansoprazole | 27 | $10,826 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 48 | $8,213 |
| Budesonide DrBudesonide | 45 | $6,895 |
| Mesalamine ErMesalamine | 19 | $5,392 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 33 | $5,342 |
| Lubiprostone | 34 | $3,563 |
| Colesevelam Hcl | 22 | $3,031 |
| Pantoprazole Sodium | 257 | $2,749 |
| Colestipol Hcl | 21 | $2,037 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 11 | $1,510 |
| Omeprazole | 87 | $1,217 |
| Imipramine Hcl | 19 | $720 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $2,838 | $317,97511 claims |
| AbbVieLinzess, Creon | $6,197 | $141,572139 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $453 | $8,21348 claims |
| Braintree Laboratories, Inc.Sutab | $164 | $5,34233 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu | $812 | $1,51011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 614 internal medicine providers in Arkansas.
Other internal medicine in Little Rock
- Priyantha WijewardaneLittle Rock$43.6M
- Joseph RoseLittle Rock$1.1M
- Alexander KaczenskiLittle Rock$305K
- Manisha SinghLittle Rock$71K
- Srikanth VallurupalliLittle Rock$34K
- Aaron StrobelLittle Rock$32K
- Ritesh RampureLittle Rock$13K
- Milton RoachLittle Rock$12K
- Michael CloudLittle Rock$10K
- Larry WatkinsLittle Rock$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.